Hosted on MSN3mon
SRPT Inks $11B Licensing Deal With Arrowhead for Rare Gene TherapiesThe remaining candidates, ARO-MMP7 and ARO-ATXN2, are being developed to treat ... especially the recently approved DMD gene therapy Elevidys. Year to date, Sarepta Therapeutics’ shares have ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback